oligonucleotide


Also found in: Medical, Encyclopedia, Wikipedia.

ol·i·go·nu·cle·o·tide

 (ŏl′ĭ-gō-no͞o′klē-ə-tīd, -nyo͞o′-, ō′lĭ-)
n.
A short polymer of two to twenty nucleotides.

oligonucleotide

(ˌɒlɪɡəʊˈnjuːklɪəˌtaɪd)
n
(Biochemistry) a polymer consisting of a small number of nucleotides

ol•i•go•nu•cle•o•tide

(ˌɒl ɪ goʊˈnu kli əˌtaɪd, -ˈnyu-)

n.
a chain of a few nucleotides.
[1940–45]
References in periodicals archive ?
Principal services include but are not confined to protein-protein conjugation, particle conjugation, oligonucleotide conjugation, biotin labeling, fluorescent dyes labeling, special labeling like europium and ruthenium, etc.
Eurofins Genomics is a leader in oligonucleotide synthesis, Sanger sequencing, next generation sequencing, and gene synthesis.
Spring Bank Pharmaceuticals announced that it has entered into a research agreement with The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to evaluate Spring Bank's hepatitis B virus antisense oligonucleotide compounds.Spring Bank has entered into a non-clinical evaluation agreement to access NIAID's preclinical services program to further evaluate Spring Bank's HBV antisense oligonucleotide compounds.
"We are excited to expand our oligonucleotide research and development efforts through this strategic collaboration with Avidity," said Andrew C.
In addition, on April 5th, the company celebrated the grand opening of an approximately 2000 m2 building, expanding oligonucleotide synthesis and supply capabilities (ug to 10 kg) to support customer needs.
Aptamers are oligonucleotide or peptide molecules that bind to a specific target molecule.
Focused presentations on oligonucleotide therapies, opportunities and challenges in drug developments, and securing oligonucleotide supply include:
[USPRwire, Thu Dec 27 2018] The expanding database of Market Research Reports Search Engine (MRRSE) has been recently updated by the addition of a new study which is titled as " Global Oligonucleotide Synthesis Market Analysis & Evolving Opportunities Studied for the Period Until 2025 ".
has presented research on its first-in-class medicines at the Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in Cambridge, Massachusetts, the company said.
The core-shell particles deliver the separation power necessary to accurately resolve closely related synthetic oligonucleotide sequences.